Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Dana-Farber Cancer Institute
- Study ID
- NCT03692325
- Phase
- PHASE2
- Status
- Completed
Conditions
- Leukoplakia, Oral
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — DRUGNivolumab is a type of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
Study Details
This research study is studying an immunotherapy drug, as a possible treatment for oral proliferative verrucous leukoplakia (OPVL).
Key Dates
- Start date
- Dec 5, 2018
- Status verified
- Sep 2024
- Primary completion
- Sep 1, 2022
- Completion
- Aug 30, 2024
Study Design
- Enrollment
- 33 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- PREVENTION
Arms
- Experimental: Nivolumab* Nivolumab will be administered by IV infusion on Day 1 of each 28-day cycle * Treatment with the study drug will continue for a maximum of 4 cycles or until unacceptable toxicity or withdrawal of consent
Primary Outcome Measure
Best Overall Response Rate (BORR) [ Time Frame: Participants were followed up to 164 days. ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | - |
Find similar trials in Boston, MA
By research site